Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05946122

Enrollment

106

Registered

2023-07-14

Start date

2023-05-30

Completion date

2023-12-30

Last updated

2023-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Protection

Brief summary

Offering renal protection in systemic inflammatory response syndrome by atorvastatin

Interventions

DRUGAtorvastatin 40 Mg Oral Tablet

oral atorvastatin for renal protection

DRUGplacebo drug

tablet resembles atorvastatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

25 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients ( male and female) with systemic inflammatory response ( total leucocytic count \>12,000 mm3'. temperature \>38 C, Heart rate \>90 b/min and respiratory rate\>20 cycle).

Exclusion criteria

* Hemodynamic instability * Pre-admission chronic kidney disease. * Intra-vascular coagulopathy * Patients with myopathy.

Design outcomes

Primary

Measure	Time frame	Description
Acute kidney injury	one week	incidence or acute kidney injury

Secondary

Measure	Time frame	Description
renal resistive vascular index	one week	renal resistive index
APACHE score ( acute physiology and chronic health evaluation)	one week	acute physiology and chronic health evaluation, values below 40 are considered normal while values between 41 and 71 are considered abnormal .
length of ICU stay	two weeks	days of ICU admission

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026